Pressure for drug development in lysosomal storage disorders – a quantitative analysis thirty years beyond the US orphan drug act

Konstantin Mechler¹, William K Mountford², Georg F Hoffmann³ and Markus Ries³*
progressive disorders of significant morbidity with decreased life-expectancy that can manifest within a heterogeneous somatic and neurological spectrum such as hydrops fetalis, dysmorphism, dysostosis multiplex, hepatosplenomegaly, central nervous system disease, ophthalmologic, cardiovascular, renal, or cutaneous disease features [5].

**U.S. orphan drug act**

Whereas the impetus to develop drugs is driven by unmet medical need, from a pharmaceutical company’s perspective, this is predicated on returns on investment, ultimately influenced by the likelihood of success in clinical trials and commercialization. The US Orphan Drug Act passed in 1983 with the goal to stimulate the investment into the development of medicines for rare diseases through various incentives, such as seven years’ marketing exclusivity, tax credit for 50% of clinical trial costs, protocol assistance, Food and Drug Administration fee waiver, and orphan products grants program [6]. By December 2013, a total of 456 orphan indications were approved by the FDA [7].

The key factors for successful drug development of therapies for lysosomal storage disorders have not been systematically analyzed. We therefore directed our efforts in assessing which lysosomal diseases had drug development pressure and what distinguished those with successful development and approvals from diseases not treated or with no orphan drug designations. Neurological endpoints were a focus of this study because many lysosomal storage disorders are neurological conditions. We analyzed whether disease prevalence, technology platforms, endpoints in clinical trials, and regulatory precedent were associated with successful drug development.

**Methods**

**Data acquisition**

We searched the FDA database for orphan drug designations with pertinent keywords for all lysosomal storage disorders at http://www.accessdata.fda.gov/scripts/opdlisting/oopd/. Start date of data entry was 01/01/1983. All data entries until 11/30/2013 were considered.

Epidemiological data on rare disorders were extracted from the Orphanet Report series [8]. Information on clinical studies were obtained from clinicaltrials.gov.

In order to account for publication bias, data on registration studies were obtained from the current FDA approved drug label accessed at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/.

**Definitions**

Pharmacological compounds were categorized into the following technology platforms based on their biochemical and therapeutic characteristics: enzyme replacement therapy, substrate reduction therapy, small molecules facilitating intracellular substrate transport, chemical chaperones, gene therapy, stem cell therapy, and others (such as adjunctive therapies). Regulatory precedent was defined as a drug approval by the FDA in the same or a clinically very similar disease, such as the different forms of mucopolysaccharidoses (MPSs). Time to FDA approval was defined as the time period from orphan drug designation until approval by the FDA.

**Statistical analysis**

Characteristics from each of the identified pharmacological compounds were summarized using descriptive statistics. Continuous variables were summarized with mean, standard deviation, median, minimum and maximum values. Categorical variables were summarized with frequencies and percentages. Key compound characteristics, including requirement for neurological endpoints in clinical trials, regulatory precedent, disease prevalences (categorized either as <5/1,000,000 or ≥5/100,000) were compared for those compounds receiving orphan drug designation as well as receiving FDA approval to determine if associations existed. Tests for associations between categorical variables were performed using Fisher’s Exact Test as a result of low cell counts, where a two-sided p-value < 0.05 was considered statistically significant. All statistical analyses were performed using SAS Enterprise Guide version 9.1 (SAS, Cary, NC, USA).

**Results**

**Successfully developed therapies**

From 1983 until 2013, fourteen drugs for seven lysosomal storage disorders received FDA approval (Figure 1, Table 1). Two conditions had multiple drug approvals: Gaucher disease (N = 5) and cystinosis (N = 3). Five conditions had one FDA drug approval, respectively: Fabry disease, Pompe disease, MPS I, MPS II, and MPS VI (Figure 2). The first drug approved with orphan designation for a lysosomal storage disorder was alglucerase for Gaucher disease in 1991.

Alglucerase had the first orphan drug designation which occurred in 1985. Most designations in a single year were granted in 2008 and 2013 with nine designations per year, respectively (Figures 1 and 3). From 1983 until 2013, orphan drug status was designated 70 times for 20 conditions of lysosomal storage disorders. Five diseases had a single orphan drug designation and 15 diseases had multiple orphan drug designations (Figure 4). Four designations were withdrawn. The mean (standard deviation) time between orphan drug designation and approval was 6.2 (3.9) years with a median of 5.5 years and a range of 1 – 15 years (N = 14). Figure 2 demonstrates the variability in time from orphan drug designation to approval for the various technology platforms and conditions.
Factors associated with successful drug development for lysosomal storage diseases

1) Prevalence of disease

The proportions of drugs receiving FDA approval and orphan drug designations were higher in rare diseases than in very rare diseases: of the 14 FDA approved drugs, 12 were for more frequent lysosomal storage diseases (prevalence $\geq 5/1,000,000$) and only two were for less frequent conditions (prevalence $< 5/1,000,000$; $p = 0.00742$) (Table 2). Likewise, orphan drug designations were granted for 45 drugs developed to treat lysosomal storage disorders with a prevalence of $\geq 5/1,000,000$, whereas only 25 drugs for less frequent diseases with a prevalence of $< 5/1,000,000$ received orphan drug designations, and in 17 very rare diseases, there was no drug in development at all ($p < 0.0001$).

2) Neurological vs somatic endpoints and biomarkers

Neurological endpoints were statistically significant factors for successful drug development and orphan drug designations (Table 2). Of the approved 14 compounds, no clinical development program had a primary neurological endpoint. Most, i.e. 51/70 (72.9%), orphan drug designations were sought for diseases that would, by nature of the disease, not require a neurological endpoint in clinical studies. In contrast, most conditions without an orphan drug designation, i.e. 15/17 (88.2%), would require a clinical trial with a neurological endpoint. Three successful orphan drug programs were based on biomarkers, i.e. in Gaucher disease, Fabry disease, and cystinosis (Table 1). The time to FDA approval for these three conditions tended to be shorter than for conditions with clinical endpoints, although the difference was not statistically different.

3) Regulatory precedent

Regulatory precedent, i.e. a drug approval in the same or a clinically very similar disease (e.g. the MPS group), was a statistically significant factor for orphan drug designation in lysosomal storage diseases (Table 2). Most orphan drug designations, i.e. 39/70 (55.7%) had a regulatory precedent whereas, accordingly, there was no regulatory precedent for the majority of lysosomal storage diseases without orphan drug status, i.e. 16/17 (94.1%, $p = 0.00022$).

4) Technology platforms

Approved therapies were enzyme replacement therapies ($N = 10$), small molecules ($N = 3$), and substrate reduction therapies ($N = 1$) as shown in Table 1. The most frequent orphan drug designations were enzymes of various sources and modified enzymes ($N = 40$), gene therapies ($N = 9$), small molecules ($N = 6$), substrate reduction therapies ($N = 6$), chaperones ($N = 6$), stem cell therapy ($N = 1$), and others ($N = 2$) as shown in Figure 4.

Discussion

In the last three decades from 1983 until 2013, fourteen drugs for seven lysosomal storage disorders received FDA approval.

There were four factors that played a key role in successful orphan drug development or orphan drug designations: 1) prevalence of disease 2) endpoints 3) regulatory
| Disease                  | Compound                  | Therapeutic class | Endpoints in pivotal studies                                                                 | Primary neurological endpoints | Biomarker endpoints | Regulatory precedent | Pivotal trial design                                                                 | Ref.  |
|--------------------------|---------------------------|-------------------|-----------------------------------------------------------------------------------------------|-------------------------------|--------------------|---------------------|-------------------------------------------------------------------------------------|-------|
| MPS I                    | Laronidase                | Enzyme            | Forced vital capacity (% of predicted), 6 min walk distance                                    | No                            | No                 | No                  | RCT, 26 weeks, N = 45, mean age 15.5 years (range 6–43 years)                        | [24]  |
| MPS II                   | Idursulfase               | Enzyme            | Forced vital capacity (% of predicted), 6 min walk distance                                    | No                            | No                 | Yes                 | RCT, 53 weeks, N = 96, mean age 14.2 years (range 5–31 years)                        | [25]  |
| MPS VI                   | Galsulfase                | Enzyme            | 12 min walk distance, 3 min stair climb test (stairs/min)                                      | No                            | No                 | Yes                 | RCT, 24 weeks, N = 39, (age range 5–29 years)                                       | [26]  |
| Gaucher disease type I   | Algglucerase              | Enzyme            | Liver and spleen volume change, Hepatologic deficiencies, improved mineralization of bone, cachexia and wasting | No                            | Yes                | No                  | OLT, 36 – 52 weeks, N = 13, mean age 20.3 years (range 7–42 years)                  | [27]  |
| Gaucher disease          | Imiglucerase              | Enzyme            | Anemia and thrombocytopenia, liver and spleen volume change, decreased cachexia                | No                            | Yes                | Yes                 | RCT, 26 weeks, N = 30, mean age 32.7 years (range 12 – 69 years)                    | [28]  |
| Gaucher disease          | Taliglucerase alfa        | Enzyme            | Hemoglobin concentration, platelet count, liver and spleen volume change                        | No                            | Yes                | Yes                 | RCT, 36 weeks, N = 32, mean age 36.2 years (range 19 – 74 years)                   | [29]  |
| Gaucher disease          | Velaglucerase alfa        | Enzyme            | Hemoglobin concentration, platelet count, liver and spleen volume change                       | No                            | Yes                | Yes                 | RCT, N = 25, 52 weeks, median age 25 years, (range 4–62 years)                     | [30]  |
| Gaucher disease          | Miglucostat               | Substrate reduction | Liver and spleen volume change, hemoglobin concentration, platelet count                          | No                            | Yes                | Yes                 | OLT, 52 weeks, N = 28, mean age 44 years (range 22–69 years)                        | [31]  |
| Fabry disease            | Agalsidase beta           | Enzyme            | Reduction of GL-3 inclusions in capillary endothelium of kidney, heart and skin                 | No                            | Yes                | No                  | RCT, 20 weeks, N = 58, mean age 30.2 years (range 16–61 years)                     | [32]  |
| Pompe disease            | Alglucosidase alfa        | Enzyme (bioreactor size: 160 L) | Number of patients who died or needed invasive ventilator support | No                            | No                 | No                  | OLT, 52–106 weeks, N = 18, age range 1 month to 3.5 years                           | [33]  |
| Pompe disease            | Alglucosidase alfa        | Enzyme (bioreactor size: 4000 L) | Forced vital capacity (% of predicted), 6 min walking distance | No                            | No                 | No                  | RCT, 78 weeks, N = 90, mean age 44.4 years (range 10–70 years)                     | [34]  |
| Cystinosis               | Cysteamine bitartrate IR  | Small molecule    | Serum creatinine, calculated creatinine clearance, growth (height)                             | No                            | Yes                | No                  | OLT, N = 94, mean age 3.8 years                                                      | [35]  |
| Cystinosis               | Cysteamine ophtalmic solution | Small molecule  | Corneal Cystine Crystal Score                                                                     | No                            | Yes                | No                  | OLT, N = 283 (three studies)                                                       | [36]  |
| Cystinosis               | Cysteamine bitartrate DR  | Small molecule    | White blood cell cystine                                                                          | No                            | Yes                | Yes                 | RCT, N = 43, mean age 12 years (range 6 – 26 years)                               | [37]  |

RCT – randomized controlled trial, OLT – open label trial, IR – immediate release, DR – delayed-release, GL-3 – globotriaosylceramide.
precedent, and 4) technology platform. These data demonstrate that the efforts in drug development were directed towards more common diseases. Primarily neurological diseases were neglected, and clinical trials utilized either somatic or biomarker endpoints. Clinical studies were mainly small clinical trials. Enzyme replacement therapy was the most successful technology in the last three decades followed by small molecules and substrate reduction.

One may think that the successful development of a therapy would stop further activities in the area. The contrary seems to be the case: innovation seeds innovations and success leads to more development pressure. Once a drug is approved, further orphan drug designations follow on as illustrated in Figure 2B. Enzyme replacement therapy for non-neurological Gaucher disease was the condition that seeded and orthodromically drove innovation. In addition to being the first, Gaucher disease also has the most approved therapies and most orphan drug designations. This may not be a coincidence, because Gaucher disease is a more frequent condition and the FDA approval was based on biomarkers as well as visceral endpoints which show timely and substantial treatment effects. Biomarker based programs, such as Gaucher disease and cystinosis tended to have shorter timelines from orphan drug designation to FDA approval.

Neurological endpoints appear to be problematic. Often, the natural history of the neurological disease is ill defined, validated quantitative endpoints across languages are not available or the treatment does not address the neurological manifestation of the disease as exemplified by two studies of enzyme replacement therapy and substrate reduction therapy in neuronopathic Gaucher disease [9,10]. The fact that neurological diseases received less attention is obviously not intentional. It is due to the types of drugs in development, and in particular, their mechanisms of action, and their ability to target sites of pathology across the blood brain barrier.

Regulatory precedent, i.e. the approval of a compound in the same disease or similar disease group, sets the pathway for successful downstream drug development in the same or a very similar condition. In the case of
mucopolysaccharidoses (MPS I, II, and VI), clinical trials shared almost identical endpoints across programs, which may have facilitated the design of pivotal studies as the true validation of clinical endpoints in single rare diseases is complicated by the small size of available study populations and the slowly progressive nature of most diseases [11-13]. Likewise, the dialogue with the FDA becomes easier once the agency has become familiar with similar questions from a previous, successful drug development program. Interestingly, although approvals were focused on endpoints documenting the initial therapeutic response, the trials which have led to regulatory approval have not addressed the lifetime requirement for treatment and maintenance regimen.

Most approved and designated orphan drugs were enzymes. Substituted enzymes tend to work well on somatic endpoints and biomarkers as demonstrated in the successful clinical development programs outlined in Table 1, but the effect of enzyme replacement therapy is mainly compromised by late initiation of treatment, immune reactions against the therapeutic protein as well as incomplete accessibility of certain tissues by the protein such as skeletal muscle, bone, and especially brain [14-17]. Dose and frequency of enzyme administration are further important questions [18]. These shortcomings will direct future research.

Other successful approvals were small molecules and substrate reduction. If a lysosomal storage disease is of

Figure 3 Year of orphan drug designation for compounds intended to treat lysosomal storage diseases. A) by technology platform. B) by disease.
low prevalence and primarily a neurological condition our data would suggest low development pressure and low probability of success. This is illustrated by programs such as Niemann-Pick disease type C and Batten disease programs which neither led to the detection of strong therapeutic effects size or to FDA approval [19,20].

What must be done to address unmet needs for ultra-rare and neuronopathic lysosomal storage disorders? Various traditional and innovative technology platforms are being tested in human. As such, clinicaltrials.gov currently lists more than 70 open interventional clinical trials for lysosomal storage disorders studying enzymes, modified enzymes, substrate reduction, intrathecal drug delivery, chaperone therapy, hematopoetic stem cell transplantation, small molecules and gene therapy [21]. The results of this work will provide further insight into

![Table 2 Statistical analysis of clinical, regulatory, and epidemiological factors associated with a) FDA approval for compounds intended to treat lysosomal storage disorders and b) orphan drug designation](image)

| Characteristic                        | No FDA approval (N = 73) | FDA approval (N = 14) | P-value*  |
|---------------------------------------|--------------------------|-----------------------|-----------|
| Neurological endpoint                 | 34 (46.6%)               | 0 (0%)                | 0.00059   |
| No neurological endpoint              | 39 (53.4%)               | 14 (100%)             |           |
| Regulatory precedent                  | 40 (54.8%)               | 9 (64.3%)             | 0.15411   |
| No regulatory precedent               | 42 (57.5%)               | 5 (35.7%)             |           |
| Prevalence < 5/1,000,000              | 33 (45.2%)               | 2 (14.3%)             | 0.00742   |
| Prevalence ≥ 5/1,000,000              | 56 (76.7%)               | 12 (85.7%)            |           |
| Orphan status designation             | 17 (23.3%)               | 14 (100%)             | 0.06229   |
| No orphan status designation          | 0 (0%)                   | 0 (0%)                |           |

*P-values are from Fisher’s Exact Test.
the ability to cure CNS diseases. Drug development in neuronopathic lysosomal storage disorders may be facilitated through the availability of better instruments assessing neurological and behavioral functions in a standardized way as proposed in the NIH toolbox [22]. Quantitative natural history studies are indispensable for a better understanding of the disease, design of clinical trials and the assessment of potential treatment effects. Biomarker development and better access to biomarker-based approvals as in Gaucher disease and cystinosis may be other points of consideration [23]. All the 14 FDA-approved compounds were developed by eight mainly small, specialized biopharmaceutical companies which have, in general, experienced sustainable economic growth over time.

Limitations of this analysis
First, the designation of a compound as an orphan drug was considered a surrogate for the intent to develop a drug for a disease. Due to patent considerations, not all manufacturers may seek orphan drug designation by the FDA and information may therefore not be transparent. Second, time to approval may not reflect true development process because the time of orphan designation may be arbitrary in the drug development process. Third, the European Medicine Agency data were not formally analyzed, mainly because orphan legislation was introduced much later (2000) and the database is therefore less comprehensive. As drug development for orphan conditions is a global effort, and as the EMA orphan drug designations show similar trends (data not shown) the formal analysis of the FDA data and their impact for patients around the world are considered generalizable.

Conclusions
Since the introduction of the US orphan drug act in 1983 until 2013, 14 orphan drugs, mostly enzyme replacement therapies, were developed for lysosomal storage disorders. Drug development was driven by more frequent conditions and diseases with somatic or biomarker endpoints sharing a similar pathway to registration. Successful development seeded further innovation.

Abbreviations
FDA: Food and Drug administration; EMA: European Medicines Agency; FD: Fabry disease; GD: Gaucher disease; MPS: Mucopolysaccharidosis; NIH: National Institutes of Health.

Competing interests
KM, WM and GFH declare no competing interests. MR received consultancy fees or research grants from Alexion, GSK, Shire, and Genzyme.

Authors’ contributions
KM performed the literature review, data entry, statistical analyses, interpreted the data, provided substantial clinical and statistical input, and wrote the manuscript with MR. WM performed the statistical analysis, interpreted the data, and provided substantial clinical and statistical input. GFH interpreted the data and provided substantial clinical and statistical input. MR conceptualized and designed the study, performed the literature review, data entry, interpreted the data, provided substantial clinical and statistical input, and wrote the manuscript with KM. All authors critically reviewed the manuscript and approved the final manuscript as submitted.

Acknowledgement
We acknowledge financial support by Deutsche Forschungsgemeinschaft and Ruprecht-Karls-Universität Heidelberg within the funding program Open Access Publishing.

Author details
1Department of Child and Adolescent Psychiatry and Psychotherapy, Pediatric Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. 2Clinical Research Program, University of North Carolina Wilmington, Wilmington, NC, USA. 3Pediatric Neurology and Metabolic Medicine, Center for Rare Diseases, Center for Pediatric and Adolescent Medicine, Heidelberg University Hospital, Im Neuenheimer Feld 430, Heidelberg D-69120, Germany.

Received: 2 March 2015 Accepted: 6 April 2015
Published online: 18 April 2015

References
1. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249–54.
2. Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet. 1999;105(1–2):151–6.
3. Applegarth DA, Toone JR, Lowry RB. Incidence of inborn errors of metabolism in British Columbia, 1969–1996. Pediatrics. 2000;105(1), e10.
4. Pinto R, Caseiro C, Lemos M, Lopes L, Fontes A, Ribeiro H, et al. Prevalence of lysosomal storage diseases in Portugal. Eur J Hum Genet. 2004;12(2):87–92. doi:10.1016/S0140-6736(04)68873-9.
5. Platt F, Walkley S. Lysosomal Disorders of the Brain: Recent Advances in Molecular and Cellular Pathogenesis and Treatment. Oxford: Oxford University Press; 2004.
6. Haffner ME, Torrent-Farnell J, Maher PD. Does orphan drug legislation really answer the needs of patients? Lancet. 2008;371(9629):2041–4. doi:10.1016/S0140-6736(08)68873-9.
7. FDA. Search Orphan Drug Designations and Approvals http://www.accessdata. fda.gov/scripts/opdlistingoospdict/Index.cfm. Accessed 20 Dec 2013.
8. Orphanet Report Series, Rare Diseases collection, Prevalence of rare diseases: Bibliographic data, November 2013, Number 1: Listed in alphabetical order of disease or group of diseases, http://www.orpha.net/orphacom/cahiers/docs/GI/Prevalence_of_rare_diseases_by_alphabetical_list.pdf Accessed 20 Dec 2013.
9. Schiffmann R, Fitzgibbon EJ, Harris C, Devile C, Davies EH, Abel L, et al. Randomized, controlled trial of miglustat in Gaucher’s disease type 3. Ann Neurol. 2008;64(5):514–22. doi:10.1002/ana.21491.
10. Goker-Alpan O, Wiggs EA, Eblan MJ, Benko W, Ziegler SG, Sidransky E, et al. Cognitive outcome in treated patients with chronic neurogenic Gaucher disease. J Pediatr. 2008;153(1):89–94. doi:10.1016/j.jpeds.2007.12.023.
11. Muenzer J, Guczavas-Caligoglu M, McCandless SE, Schuetz TJ, Kinura A, A phase III clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab. 2007;90(3):329–37. doi:10.1016/j.ymgme.2006.09.001.
12. Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Enzyme replacement therapy for mucopolysaccharidosis I is randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr. 2004;144(5):818–8. doi:10.1016/j.jpeds.2004.01.046.
13. Harmatz P, Whiteley CB, Waber L, Pasi R, Steiner R, Plecko B, et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr. 2004;144(5):574–80. doi:10.1016/j.jpeds.2004.03.018.
14. Attaressi G, Hill S, Wiggs E, Jeffries N, Keen P, Parker CC, et al. The efficacy of enzyme replacement therapy in patients with chronic neurogenic Gaucher’s disease. J Pediatr. 2001;138(4):539–47.
15. Res M, Gupta S, Moore DF, Sachdev V, Quirk JM, Murray Gl, et al. Pediatric Fabry disease. Pediatrics. 2005;115(3):e344–55. doi:10.1542/peds.2004-1678.
16. Ghaziri T. Enzyme replacement therapy for lysosomal storage diseases. Pediatr Endocrinol Rev. 2012;10 Suppl 1:26–34.
17. Strothotte S, Strigl-Pill N, Grunert B, Eger K, Wessig C, et al. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol. 2010;257(1):91–7. doi:10.1007/s00415-009-5275-3.

18. Schiffmann R, Askari H, Timmons M, Robinson C, Benloko W, Brady RO, et al. Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol. 2007;18(5):1576–83. doi:10.1681/ASN.2006111263.

19. Levin SW, Baker EH, Zein WM, Zhang Z, Quezado ZM, Miao N et al. Oral cysteamine bitartrate and N-acetylcysteine for patients with infantile neuronal ceroid lipofuscinosis: a pilot study. Lancet Neurol. 2014;13(8):777–87. doi:10.1016/S1474-4422(14)70142-5.

20. Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol. 2007;6(9):765–72. doi:10.1016/S1474-4422(07)70194-1.

21. Clinicaltrials.gov. search terms: lysosomal | Open Studies | Interventional Studies https://clinicaltrials.gov/ct2/results?term=lysosomal&recr=Open&type=Int&pg=4. Accessed 20 Feb 2015.

22. Gershon RC, Cella D, Fox NA, Havlik RJ, Hendrie HC, Waigster MV. Assessment of neurological and behavioural function: the NIH Toolbox. Lancet Neurol. 2010;9(2):138–9. doi:10.1016/S1474-4422(09)70335-7.

23. Bradbury AM, Gray-Edwards HL, Shirley JL, McCurdy VJ, Colaco AN, Randle AN, et al. Biomarkers for disease progression and AAV therapeutic efficacy in feline Sandhoff disease. Exp Neurol. 2015;263:102–12. doi:10.1016/j.expneurol.2014.09.020.

24. FDA. Laronidase Product Approval Information - Licensing Action http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080438.htm. Accessed 20 Dec 2013.

25. FDA. Drug Approval Package: Elaprase (Idursulfase) NDA # 125151 http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/125151s000_125151s000_Toc.cfm. Accessed 20 Dec 2013.

26. FDA. Drug Approval Package: Naglazyme (Galsulfase) NDA #125117 http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/125117s000_125117s000_Toc.cfm. Accessed 20 Dec 2013.

27. FDA. Drug Approval Package: Cerezyme, NDA no. 020367, label http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/20367s066lbl.pdf. Accessed 20 Dec 2013.

28. FDA. Drug Approval Package: Zavesca (Miglustat) http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-348_Zavesca.cfm. Accessed 20 Dec 2013.

29. FDA. Drug Approval Package: Myozyme (Alglucosidase Alfa) NDA # 125141 http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/125141s000_MyozymeTOC.cfm. Accessed 20 Dec 2013.

30. FDA. Drug Approval Package: Vpriv (Velaglucerase alfa) http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022575s000TOC.cfm. Accessed 20 Dec 2013.

31. FDA. Drug Approval Package: Lumizyme (alglucosidase alfa) http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125291s000TOC.cfm. Accessed 20 Dec 2013.

32. FDA. Drug Approval Package: PROCYSBI, NDA no. 203389, label http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203389s000lbl.pdf. Accessed 20 Dec 2013.